Figure 1From: Gender-specific distribution of mefloquine in the blood following the administration of therapeutic dosesScatter plot and regression line for mefloquine plasma concentrations (ng/ml) and overall symptom score. The frequency, duration and severity of adverse events (represented by OSS) exhibited significant correlation with mefloquine plasma levels (y = 0.0085x + 16.465, r = 0.519; p = 0.016).Back to article page